VOTING PROXY AND INSTRUCTIONS
Voting proxy for annual general meeting of shareholders ("Meeting") of
Kiadis Pharma N.V. ("Kiadis Pharma")
to be held on Monday 28 June 2021 at 15:00 Central European Summer Time (CEST)
VOTING PROXY
THE UNDERSIGNED:
……………..………………………………………………………………………………………….. (name)
…………...……………………………………………………………………………………….... (address)
……...…………………………………………………………………………………. (postal code & town)
…………………………………………………………………………………………………….... (country)
……...……………………………………………………………………………(legal entity that holds the shares)
…………………………………………………………………………………………………….... (e-mailaddress Shareholder)
hereinafter referred to as the "Shareholder", acting in his/her capacity as holder of …………………
(number) shares in the capital of Kiadis Pharma (the "Shares"),
hereby authorizes Mr. Frank Nestle (member of the Supervisory Board of Kiadis Pharma) to, for and on behalf of the Shareholder, attend the Meeting, sign the attendance list and exercise the voting right for the Shares held by the Shareholder as per the below voting instructions (page 2), all with the power of substitution. In absence of a clear voting instruction, the votes will be cast in favor of the resolutions.
NOTES:
- A Shareholder can only exercise his/her voting right priorto the Meeting and should do so by returning a completed and duly signed version of this proxy and voting instructions form no later than 15:00 CEST on Monday 21 June 2021. The completed and signed form can be sent to Van Lanschot Kempen Wealth Management N.V. (telefax number: +31 (0)20 348 9549 or e-mail address: proxyvoting@kempen.nl) or to Kiadis Pharma (e-mail address: AGM2021@kiadis.com). For detailed instructions the Shareholder should consult the convocation notice for the Meeting that is published on the Kiadis Pharma website (www.kiadis.com).
- Any alterations made to this form of proxy should be initialed by the Shareholder.
- This voting proxy is governed by Dutch law.
[ REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK ]
1
VOTING INSTRUCTIONS
Agenda item | For | Against | Abstain |
Agenda Item 2 - Adoption Financial Statements 2020 | |||
Agenda Item 3 - Discharge of the members of the Management | |||
Board | |||
Agenda Item 4 - Discharge of the members of the Supervisory | |||
Board | |||
Agenda Item 5 - Full and final discharge of Mr. Arthur Lahr | |||
Agenda Item 6 - Appointment of Mr. Dirk de Naeyer as a | |||
member of the Management Board | |||
Agenda Item 7 - Appointment of Mr. Pieter Oldenziel as a | |||
member of the Management Board | |||
Agenda Item 8 - Appointment of Ernst & Young Accountants LLP | |||
as Kiadis Pharma's external auditor for the financial year 2021 | |||
Agenda Item 9 - Conditional approval of the amendment of the | |||
Rules of Procedure of the Supervisory Board | |||
Agenda Item 10 - Conditional approval of the amendment of the | |||
Rules of Procedure of the Management Board | |||
Signature: ………………………………………………………………………
Date: ………………………… 2021
2
Attachments
- Original document
- Permalink
Disclaimer
Kiadis Pharma NV published this content on 13 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 May 2021 15:55:07 UTC.